Regulation 3 Amendment of regulation 2 of the 2001 Regulations
In regulation 2(1) of the 2001 Regulationsf1 (interpretation) at the appropriate places insert—
““cannabis-based product for medicinal use in humans” means a preparation or other product, other than one to which paragraph 5 of part 1 of Schedule 4 applies, which—
- (a)
is or contains cannabis, cannabis resin, cannabinol or a cannabinol derivative (not being dronabinol or its stereoisomers);
- (b)
is produced for medicinal use in humans; and—
- (c)
is—
- (i)
a medicinal product, or
- (ii)
a substance or preparation for use as an ingredient of, or in the production of an ingredient of, a medicinal product;”;
““clinical trial” has the same meaning as in the Medicines for Human Use (Clinical Trials) Regulations 2004f2;”;
““dronabinol” does not include any substance which—
- (a)
has the international non-proprietary name dronabinol (recommended by the World Health Organisation); and
- (b)
is derived from cannabis, cannabis resin or their constituents,
and stereoisomers of dronabinol are to be construed accordingly;; and”; and
““medicinal product” has the same meaning as in the Human Medicines Regulations 2012f3;”.
Annotations
Footnotes
- f1
-
Regulation 2 has been amended by S.I. 2003/1653, 2003/2429, 2004/1771, 2005/271, 2005/2864, 2006/986, 2006/1450, 2006/2178, 2007/2154, 2011/2581, 2012/973, 2012/1916, 2013/235, 2015/891 and 2018/682.
- f2
-
S.I. 2004/1031. See the definition of “clinical trial” in regulation 2.
- f3
-
S.I. 2012/1916. See the definition of “medicinal product” in regulation 2.